SCHEMBL3337258

SCHEMBL3337258

N#Cc1ccc(-c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.66
RAB9A P51151 6/20 0.66
GAA P10253 1/20 0.66
KDM4E B2RXH2 6/20 0.63
ALDH1A1 P00352 6/20 0.63
SMN1; SMN2 Q16637 5/20 0.63
HSD17B10 Q99714 3/20 0.63
HPGD P15428 3/20 0.63
TP53 P04637 2/20 0.63
MAPT P10636 2/20 0.63
POLB P06746 1/20 0.63
GFER P55789 1/20 0.63
ATR Q13535 1/20 0.62
RHEB Q15382 1/20 0.61
CHEK2 O96017 1/20 0.60
PKN1 Q16512 2/20 0.60
PKN2 Q16513 2/20 0.60
PKM P14618 3/20 0.58
DGAT1 O75907 1/20 0.58
SOAT1 P35610 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL484587 0.98 NPC1 (0.64) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL2178266 0.86 NPC1 (0.88) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL29386825 0.86 NPC1 (0.88) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL28594113 0.85 SMN1; SMN2 (0.59) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL24295036 0.84 NPC1 (0.84) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL20982583 0.83 RHEB (0.70) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL13947208 0.83 NPC1 (0.66) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL3338846 0.83 KDM4E (0.61) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL22499602 0.82 NPC1 (0.81) NPC1RAB9AGAAKDM4EALDH1A1
SCHEMBL16147689 0.82 CHEK2 (0.56) NPC1RAB9AGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195432-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-01-14 US disclosed
WO-2024137505-A2 METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION TRANQUIS THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
CN-118047723-A Process for preparing benzoazacyclic compounds 常州大学 2024-05-17 CN disclosed
CN-110759903-B Novel synthesis method of thiabendazole 南开大学 2022-10-28 CN disclosed
US-20210300877-A1 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-09-30 US disclosed
US-11111217-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-09-07 US disclosed
US-20210061769-A1 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-03-04 US disclosed
US-10851066-B2 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-12-01 US disclosed
US-20200299244-A1 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-09-24 US disclosed
WO-2020033359-A1 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-02-13 WO disclosed
US-9169282-B2 Metal complexes MERCK PATENT GMBH (DE) 2015-10-27 US disclosed
US-9169282-B2 Metal complexes MERCK PATENT GMBH (DE) 2015-10-27 US disclosed
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2014-09-18 US disclosed
WO-2013074059-A2 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2013-05-23 WO disclosed
US-8198307-B2 Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-06-12 US disclosed
US-20110284799-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2011-11-24 US disclosed
US-20110284799-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2011-11-24 US disclosed
WO-2010086089-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2010-08-05 WO disclosed
US-20100145054-A1 IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-10 US disclosed
EP-0479161-A1 Synthesis of heterocyclic compounds EASTMAN CHEMICAL COMPANY (US) 1992-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299244-A1 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES PPARG, PPARA, PPARD NPC1 379/4885RAB9A 1910/4885GAA 1324/4885
US-20210300877-A1 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES PPARG, PPARA, PPARD NPC1 989/4885RAB9A 2214/4885GAA 382/4885
US-20210061769-A1 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES PPARG, PPARA, PPARD NPC1 502/4885RAB9A 2015/4885GAA 1555/4885
US-20110284799-A1 METAL COMPLEXES SOD1, AP1M1, AP3M1 NPC1 3516/4885RAB9A 2201/4885GAA 3358/4885
US-11111217-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases PPARG, PPARA, PPARD NPC1 502/4885RAB9A 2015/4885GAA 1555/4885
US-10851066-B2 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases PPARG, PPARA, PPARD NPC1 379/4885RAB9A 1910/4885GAA 1324/4885
US-12195432-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases PPARG, PPARA, PPARD NPC1 989/4885RAB9A 2214/4885GAA 382/4885
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION CDA, DCTD, ADA NPC1 498/4885RAB9A 2645/4885GAA 68/4885
US-20100145054-A1 IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME TYR, MCHR1, MCHR2 NPC1 223/4885RAB9A 687/4885GAA 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.